Abstract
Breast cancer is the most prevalent cancer in women and presently, the breast cancer survivors are an important group of women that faced the several consequences of estrogen deficiency, which is especially common in women after chemotherapy. The most bothersome is the vasomotor symptoms, which are effectively relieved by hormonal therapy (HT). Also, the increased risk of osteoporosis and coronary artery disease is major problem to be resolved in pos of maintaining a good quality of life. Fearing cancer recurrence, most physicians do not offer HT to women with a history of breast cancer. Over this issue reviews the available evidence of the use of HT and tibolone in women treated for breast cancer.
| Original language | American English |
|---|---|
| Pages (from-to) | 10-15 |
| Number of pages | 6 |
| Journal | Gynecological Endocrinology |
| Volume | 33 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2 Jan 2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Breast cancer
- cancer survivors
- estrogen–progestin therapy
- hormone therapy
- menopausal symptoms
- tibolone
Fingerprint
Dive into the research topics of 'Use of hormone therapy for menopausal symptoms and quality of life in breast cancer survivors. Safe and ethical?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver